title: Structural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: a combined in silico study.
abstract: Chemokine receptors are G protein-coupled receptors that contain seven transmembrane domains. In particular, CCR2 and CCR5 and their ligands have been implicated in the pathophysiology of a number of diseases, including rheumatoid arthritis and multiple sclerosis. Based on their roles in disease, they have been attractive targets for the pharmaceutical industry, and furthermore, targeting both CCR2 and CCR5 can be a useful strategy. Owing to the importance of these receptors, information regarding the binding site is of prime importance. Structural studies have been hampered due to the lack of X-ray crystal structures, and templates with close homologs for comparative modeling. Most of the previous models were based on the bovine rhodopsin and β2-adrenergic receptor. In this study, based on a closer homolog with higher resolution (CXCR4, PDB code: 3ODU 2.5 Å), we constructed three-dimensional models. The main aim of this study was to provide relevant information on binding sites of these receptors. Molecular dynamics simulation was done to refine the homology models and PROCHECK results indicated that the models were reasonable. Here, binding poses were checked with some established inhibitors of high pharmaceutical importance against the modeled receptors. Analysis of interaction modes gave an integrated interpretation with detailed structural information. The binding poses confirmed that the acidic residues Glu291 (CCR2) and Glu283 (CCR5) are important, and we also found some additional residues. Comparisons of binding sites of CCR2/CCR5 were done sequentially and also by docking a potent dual antagonist. Our results can be a starting point for further structure-based drug design.
authors.affiliation: Department of Bio-New Drug Development, College of Medicine, Chosun University, Gwangju, Korea.
authors.forename: Gugan
authors.initials: G
authors.lastname: Kothandan
authors.forename: Changdev G
authors.initials: CG
authors.lastname: Gadhe
authors.forename: Seung Joo
authors.initials: SJ
authors.lastname: Cho
mesh_terms: D000595:Amino Acid Sequence; D001549:Benzamides / Q000737:chemistry / Q000378:metabolism; D001665:Binding Sites / Q000235:genetics; D003510:Cyclohexanes / Q000737:chemistry / Q000378:metabolism; D018698:Glutamic Acid / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D006801:Humans; D000077592:Maraviroc; D008958:Models, Molecular; D056004:Molecular Dynamics Simulation; D008969:Molecular Sequence Data; D015394:Molecular Structure; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D011759:Pyrrolidines / Q000737:chemistry / Q000378:metabolism; D054390:Receptors, CCR2 / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D019713:Receptors, CCR5 / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D017386:Sequence Homology, Amino Acid; D014230:Triazoles / Q000737:chemistry / Q000378:metabolism
chemical_list: D001549:Benzamides; D003510:Cyclohexanes; C541285:N-(carbamoylmethyl)-3-trifluoromethyl benzamido-4-chlorobenzyl 3-aminopyrrolidine; D011759:Pyrrolidines; D054390:Receptors, CCR2; D019713:Receptors, CCR5; D014230:Triazoles; D018698:Glutamic Acid; D000077592:Maraviroc